PMID- 36909152
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230314
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide 
      for connective tissue disease-associated interstitial lung disease: A 
      meta-analysis of randomized controlled trials.
PG  - 1064578
LID - 10.3389/fphar.2023.1064578 [doi]
LID - 1064578
AB  - Objectives: To evaluate the effectiveness and safety of Chinese herbal medicines 
      (CHMs) combined with cyclophosphamide (CTX) for connective tissue 
      disease-associated interstitial lung disease (CTD-ILD) by performing a 
      meta-analysis. Methods: We searched RCTs of Chinese herbal medicines therapy for 
      connective tissue disease-associated interstitial lung disease in ten databases. 
      Methodological quality assessment was performed by the Cochrane collaboration 
      tool. RevMan v5.3 and Stata v14.0 software were used for performing data 
      analysis. This study was conducted and reported following the PRISMA checklist. 
      Results: Overall, seven RCTs with 506 participants were included for this 
      analysis. Current data indicated that Chinese herbal medicines combined with 
      cyclophosphamide contributed to a betterment in improving the clinical efficacy 
      rate of connective tissue disease-associated interstitial lung disease [risk 
      ratio (RR) = 1.21, 95% confidence interval (CI): (1.09, 1.35), p = 0.0003], 
      tended to benefit improvement of lung function, which included VC [weighted mean 
      difference (WMD) = 9.49, 95% CI: (5.54, 13.45), p < 0.00001], FVC [standardized 
      mean difference (SMD) = 0.83, 95% CI: (0.36, 1.29), p = 0.0005], FEV1 [SMD = 
      0.54, 95% CI: (0.23, 0.86), p = 0.0008], TLC [SMD = 0.90, 95% CI: (0.68, 1.13), p 
      < 0.00001], DLCO [SMD = 1.05, 95% CI: (0.38, 1.73), p = 0.002], and MVV [SMD = 
      0.83, 95% CI: (0.50, 1.17), p < 0.00001], and it also could significantly reduce 
      the HRCT integral of lungs [SMD = -2.02, 95% CI: (-3.14, -0.91), p = 0.0004] and 
      the level of ESR [WMD = -13.33, 95% CI: (-18.58, -8.09), p < 0.00001]. 
      Furthermore, there was no statistical significance in the incidence of adverse 
      events (AEs), which indicate that Chinese herbal medicines combined with 
      cyclophosphamide is safe and does not increase adverse events compared with 
      cyclophosphamide alone. Conclusion: Our analysis indicates that Chinese herbal 
      medicines combined with cyclophosphamide may be a more effective strategy on the 
      treatment of connective tissue disease-associated interstitial lung disease in 
      the clinic. Because it included studies with relatively small sample size, the 
      results need to be confirmed by more well-designed and large-scale RCTs. 
      Systematic Review Registration: https://10.37766/inplasy2022.12.0010.
CI  - Copyright (c) 2023 Yin, Zhao, Xiang, Chen, Xu and Zhang.
FAU - Yin, Xietian
AU  - Yin X
AD  - College of the First Clinical, Hubei University of Chinese Medicine, Wuhan, 
      China.
AD  - Department of Rheumatism Immunology, Hubei Provincial Hospital of TCM, Wuhan, 
      China.
FAU - Zhao, Shichao
AU  - Zhao S
AD  - Department of Geriatrics, Hubei Provincial Hospital of TCM, Wuhan, China.
FAU - Xiang, Nan
AU  - Xiang N
AD  - College of the First Clinical, Hubei University of Chinese Medicine, Wuhan, 
      China.
FAU - Chen, Jidong
AU  - Chen J
AD  - College of the First Clinical, Hubei University of Chinese Medicine, Wuhan, 
      China.
FAU - Xu, Jun
AU  - Xu J
AD  - College of the First Clinical, Hubei University of Chinese Medicine, Wuhan, 
      China.
FAU - Zhang, Yudan
AU  - Zhang Y
AD  - Hubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic 
      Diseases, Hubei Minzu University, Enshi, China.
LA  - eng
PT  - Systematic Review
DEP - 20230223
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9995361
OTO - NOTNLM
OT  - Chinese herbal medicine (CHM)
OT  - connective tissue disease-associated interstitial lung disease
OT  - cyclophosphamide
OT  - metaanalysis
OT  - randomized controlled trials
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/14 06:00
MHDA- 2023/03/14 06:01
PMCR- 2023/02/23
CRDT- 2023/03/13 03:55
PHST- 2022/10/08 00:00 [received]
PHST- 2023/02/13 00:00 [accepted]
PHST- 2023/03/13 03:55 [entrez]
PHST- 2023/03/14 06:00 [pubmed]
PHST- 2023/03/14 06:01 [medline]
PHST- 2023/02/23 00:00 [pmc-release]
AID - 1064578 [pii]
AID - 10.3389/fphar.2023.1064578 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Feb 23;14:1064578. doi: 10.3389/fphar.2023.1064578. 
      eCollection 2023.